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ABBREVIATIONS
AIB1 amplified in breast cancer 1 gene
AKT2 gene encoding a serine-threonine protein kinase-related protein
kinase c
BAC bacterial artificial chromosome
BARD1 BRCA1-associated ring domain 1
BCL2 B-cell CLL/lymphoma-2 gene
BFL1 BCL2-related gene, murine A1 homolog
bp base pair
BRCA1 breast cancer gene 1, early onset
BRCA2 breast cancer gene 2, early onset
cdc42 gene for cell division cycle 42 homolog
CDKN2 cyclin-dependent kinase inhibitor 2A gene, MTS1
cDNA complementary DNA
CGH comparative genomic hybridization
CK7 gene for keratin 7
CK18 gene for keratin 18
CK19 gene for keratin 19
CMET hetocyte growth factor receptor gene
CMYC v-myc avian myelocytomatosis viral oncogene homolog
COL3A1 gene for collagen type 3 alpha 1
DAPI 4’, 6-diamidino-2-phenylindole
DCC deleted in colorectal cancer gene
dCTP deoxycytidine triphosphate
DES gene for desmin
DLG3 discs, large (Drosophila) homolog 3 gene, neuroendocrine-dlg
DNA deoxyribonucleic acid
DOC2 differentially expressed in ovarian carcinoma gene
DOP degenerate oligonucleotide-primed
dUTP deoxyuridine triphosphate
ERBB2 avian erythroblastic leukemia viral oncogene homolog 2
EST expressed sequence tag
FEZ1 gene for fasciculation and elongation protein zeta 1, zygin I
FGFRI fibroblast growth factor receptor 1 gene
FIGO International Federation of Gynecology and Obstetrics
FISH fluorescence in situ  hybridization
FITC fluorescein isothiocyanate
FZD3 gene for frizzled, drosophila homolog 3
HGF hepatocyte growth factor
HGFAC HGF activator gene
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HNPCC hereditary nonpolypotic colorectal cancer
hRAD51 RAD51 (S. cerevisiae) homolog (E. coli RecA homolog), DNA repair
protein rad51 homolog 1
HRAS1 Harvey rat sarcoma viral (v-Ha-ras) oncogene 1 homolog
HTLV-1 human T-cell leukemia virus 1
hTR human telomerase RNA gene
IGFBP4 gene for insulin-like growth factor-binding protein 4
INT2 fibroblast growth factor 3 gene, murine mammary tumor virus inte
gration site (v-int-2) oncogene homolog
kb kilobase
KRAS kirsten rat sarcoma 2 viral oncogene homolog
LMP low malignant potential
LOH loss of heterozygosity
MLH1 mutL (E. coli) homolog 1 gene
MMP2 matrix metalloproteinase 2 gene
MMP7 matrix metalloproteinase 7 gene
MSH2 mutS (E. coli) homolog 2 gene
MSH6 mutS (E. coli) homolog 6 gene
MSR macrophage scavenger receptor gene
MTS1 cyclin-dependent kinase inhibitor 2A gene, CDKN2
N33 putative prostate cancer suppressor gene
OVCA1 ovarian cancer gene 1
OVCA2 ovarian cancer gene 2
p short arm of the chromosome
PAC P1 artificial chromosome
PCNA gene for proliferative cellular nuclear antigen
PCR polymerase chain reaction
PDGFRA gene for platelet-derived growth factor receptor alpha
PIK3CA phosphatidylinositol 3-kinase gene
PMS1 post-meiotic segregation increased (S. cerevisae)-like 1 gene
PMS2 post-meiotic segregation increased (S. cerevisae)-like 2 gene
q long arm of the chromosome
RB1 retinoblastoma-1 gene
RhoGDI1 GDP dissociation inhibitor 1 gene
RNA ribonucleic acid
Smad4 MAD (mothers against decapentaplegic, Drosophila) homolog 4 gene
TGF transforming growth factor
TIMP2 tissue inhibitor of metalloproteinase 2 gene
TP53 gene for tumor protein p53
TRITC tetramethylrhodamine
VEGF vascular endothelial growth factor gene
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INTRODUCTION
Ovarian cancer is the fourth most common
cancer among women in Finland. It carries
poor prognosis because the diagnosis is of-
ten delayed until there is advanced disease.
Early detection is hampered by the lack of
efficient diagnostic and screening methods,
and the disease remains asymptomatic un-
til advanced. Treatment comprises surgery
and chemotherapy. Despite improvements,
the overall prognosis has remained poor.
Ovarian carcinoma exhibits a wide spec-
trum of histological subtypes and biologi-
cal behavior, ranging from aggressive and
unresponsive to chemosensitive tumors. The
most important prognostic indicators are
clinical stage, histological subtype and grade,
extent of residual tumor, patient’s age and
performance status (Friedlander, 1998).
Even histopathologically identical tumors
can differ in their clinical behavior. The
natural course of the disease and its respon-
siveness to therapy can be unpredictable.
Better understanding of the biological char-
acteristics of ovarian carcinoma is needed to
develop more individualized treatment
modalities.
Despite rapid progress in cancer research,
the genetic alterations in ovarian cancer are
still incompletely understood. An impor-
tant contribution was the identification of
the tumor suppressor genes BRCA1 and
BRCA2. Inherited breast and ovarian can-
cers are known to be associated with muta-
tions in these genes. Ovarian carcinoma can
also be a manifestation of hereditary
nonpolypotic colorectal cancer (HNPCC)
syndrome. Many other cancer genes in-
volved in ovarian cancer, however, still re-
main to be disclosed.
In the past few years, the development
of new genome-wide screening techniques,
such as comparative genomic hybridization
(CGH), has played an important role in lo-
calizing possible cancer-associated genes.
CGH has facilitated identification of chro-
mosomal imbalances in human cancers
(Kallioniemi et al., 1992; du Manoir et al.,
1993). Another new approach is the so
called microarray technique, which allows
profiling of large scale gene expression.
This study is focused on molecular cyto-
genetic and molecular genetic screening and
characterization of various types of ovarian
carcinoma.
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REVIEW OF THE LITERATURE
This thesis deals with epithelial ovarian can-
cer, and later in the text ovarian cancer and
ovarian carcinoma refer to epithelial ova-
rian cancer.
1. Epidemiology of ovarian cancer
In Finland, 620 new cases of ovarian cancer
were diagnosed in 1997 (The Finnish Can-
cer Registry, 2000). The age-standardized
incidence in 1997 was 143/1,000,000 (ad-
justed for age to the World Standard Popu-
lation) (The Finnish Cancer Registry, 2000).
The cumulative incidence of ovarian cancer
by the age of 75 years is 1.4% (Auranen et
al., 1996).
2. Etiology of ovarian cancer
The causes of ovarian carcinoma are poorly
understood. The “incessant ovulation“ hy-
pothesis of epithelial ovarian cancer etiol-
ogy suggests that repeated rupture of the
ovarian surface epithelium, followed by pro-
liferation of the epithelial cells, could in-
duce malignant transformation of these cells
(Fathalla, 1971). According to the gonadot-
ropin hypothesis, high gonadotropin levels
increase the risk of cancer by stimulating
the surface epithelium of the ovary (Stadel,
1975). Pituitary gonadotropins have been
shown to stimulate the growth of human
ovarian carcinoma cell lines in vitro (Simon
et al., 1983). In addition, it is thought that
the ovary can be exposed to external car-
cinogens ascending through the vagina and
fallopian tubes.
3. Histology of ovarian cancer
Epithelial ovarian cancer accounts for about
90% of primary ovarian malignancies. It is
thought to derive from the germinal sur-
face epithelium of the ovary. During orga-
nogenesis the ovarian surface epithelium
arises from the coelomic epithelium. Ova-
rian carcinoma is a heterogeneous group of
tumors with several histological subtypes.
The most common is ovarian serous carci-
noma, which histologically resembles fal-
lopian tube epithelium and represents ap-
proximately 40–53% of all ovarian carci-
nomas. The next most common are ovarian
endometrioid carcinoma, which histologi-
cally resembles uterine endometrium (10–
24% of cases), and ovarian mucinous carci-
noma, resembling the uterine endocervix
(3–14% of cases). Other histological sub-
types consist of clear cell carcinoma (5–
11%), malignant Brenner tumor (2%),
malignant mixed epithelial tumor (5%) and
undifferentiated carcinoma (6%) (Blaustein,
1982; Heinz et al., 2001).
4. Natural course and prognosis of
ovarian cancer
Usually, ovarian carcinoma manifests after
the menopause, the mean age at onset be-
ing 62 years (Dickman et al., 1999). Ova-
rian carcinoma can, however, occur in very
young patients (Heinz et al., 2001), espe-
cially in the case of inherited ovarian can-
cer (Bewtra et al., 1992).
The overall prognosis of ovarian carci-
noma is poor, the five-year survival rate be-
Johanna Tapper
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ing 48% (Heinz et al., 2001). Of the most
common histologic subtypes, mucinous car-
cinoma has the best prognosis, the five-year
survival rate being 69% (Heinz et al., 2001).
The rates for serous and endometrioid carci-
nomas are 40% and 60%, respectively
(Heinz et al., 2001). The survival rate im-
proved slowly but steadily during the 1990s
(Dickman et al., 1999; Heinz et al., 2001).
The low survival rate reflects the aggressive
nature of the disease and delay in diagnosis.
Thus, about 70% of ovarian cancers are
advanced at the time of diagnosis. The
suitability of assay of tumor marker CA125
and abdominal or vaginal ultrasonography
have been tested for screening of ovarian
cancer, but due to the low incidence and often
rapid natural course of the disease, they are
not suitable for mass screening (Jacobs et al.,
1999). In addition, assay of CA125 and
ultrasonography are not sensitive enough for
screening purposes.
5. Inherited ovarian cancer
In addition to sporadic forms of ovarian
cancer, familial and inherited forms can
be distinguished. In the familial form, usu-
ally several cancer cases occur in a family
but the genetic background is unknown.
In the inherited form, the inherited muta-
tion in the predisposing gene, or other
genetic factor, is known. It has been esti-
mated that 5–10% of all ovarian carcino-
mas are associated with inherited germ-line
mutations of cancer-predisposing genes
(Boyd and Rubin, 1997). Here, two
distinct phenotypes can be identified. The
first is the breast and ovarian cancer syn-
drome, and the second is ovarian cancer
associated with the hereditary nonpolypotic
colorectal cancer (HNPCC) syndrome. The
breast and ovarian cancer syndrome is
linked to either the BRCA1 gene at 17q21
(Miki et al., 1994) or the BRCA2 gene at
13q12-q13 (Wooster et al., 1994).
HNPCC tumors are linked to germ-line
mutations in the mismatch repair genes
MLH1 (Papadopoulos et al., 1994), MSH2
(Leach et al., 1993), MSH6 (Edelmann et
al., 1997; Miyaki et al., 1997), PMS1 and
PMS2 (Nicolaides et al., 1994). The
BRCA1 protein is a component of an RNA
polymerase II transcription complex, and
it is thought to function as a transcription
factor (Scully et al., 1997). It has been sug-
gested that BRCA1 could be related to cell
differentiation and proliferation (Marquis
et al., 1995). An additional suggested func-
tion of BRCA1 is in the maintenance of
genomic stability, by repairing, together
with hRad51 protein, double-strand DNA
breaks (Scully et al., 1997). The results of
loss of heterozygosity (LOH) analysis and
functional studies suggest that BRCA1
may act as a tumor suppressor gene (Boyd
and Rubin, 1997). Like BRCA1, BRCA2
is classified as a tumor suppressor gene
(Boyd and Rubin, 1997). In addition,
BRCA2 interacts with hRad51 protein
and is involved in the repair of DNA
breaks (Sharan et al., 1997). Thus, BRCA1
and BRCA2 proteins share similar func-
tions.
The results of several studies suggest that
the age at onset of inherited ovarian carci-
noma is lower than that of sporadic ovarian
carcinoma, and the clinical course of
BRCA1-associated ovarian cancer is more
favorable than that of sporadic cancer
(Bewtra et al., 1992; Rubin et al., 1996).
However, the prognosis of disease in
BRCA1 mutation carriers appears to be
similar to, or even worse than that of
sporadic ovarian cancer (Johannsson et al.,
1998; Pharoah et al., 1999). It is of interest
that most BRCA1- and BRCA2-associated
ovarian carcinomas exhibit serous histology
(Narod et al., 1994; Rubin et al., 1996),
and among all forms of inherited ovarian
cancer, mucinous carcinoma and borderline
tumors are rare (Boyd and Rubin, 1997).
Within a given histological subtype,
inherited carcinoma is microscopically
indistinguishable from sporadic carcinoma
(Auranen et al., 1997).
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6. Protective and risk factors of
ovarian cancer
6.1. Sporadic ovarian cancer
Multiparity (Risch et al., 1983; Whitte-
more 1993; Adami et al., 1994), lactation
(Whittemore 1993), oral contraceptive use
(Risch et al., 1983; Whittemore 1993;
Vessey and Painter, 1995), tubal ligation
and hysterectomy (Kreiger et al., 1997;
Miracle-McMahill et al., 1997) have been
related to a decreased risk of ovarian cancer.
Behavioral characteristics, such as use of
cosmetic talc on the perineum is related to
an increased risk (Whittemore et al., 1988;
Harlow et al., 1992; Cramer et al., 1999).
The risk factors associated with the differ-
ent histological subtypes may vary (Kvale
et al., 1988; Risch et al., 1996). There is
evidence indicating that pregnancy and the
use of oral contraceptives do not give pro-
tection against mucinous cancer (Risch et
al., 1996).
6.2. Familial ovarian cancer
Of the factors other than age, a positive fam-
ily history of ovarian cancer confers the
greatest risk of ovarian cancer (Amos and
Struewing, 1993; Parazzini et al., 1991;
Schildkraut and Thompson, 1988). Women
who have first degree relatives (mother, sis-
ter or daughter) with ovarian cancer have a
two- to five-fold risk of ovarian cancer
(Schildkraut and Thompson, 1988; Hartge
et al., 1989; Parazzini et al., 1992; Auranen
et al., 1996).
6.3. Inherited ovarian cancer
Epidemiological analysis suggests that there
are families with a high incidence of breast
cancer and a low incidence of ovarian can-
cer, and families with an equally high inci-
dence of breast and ovarian cancer (Easton
et al., 1995). Here, ovarian cancer risk may
depend on the localization of the mutation
in the BRCA1 or BRCA2 gene (Gayther et
al., 1995; Gayther et al., 1997). By the age
of 70 years, in BRCA1 mutation carriers,
the cumulative risk of ovarian cancer has
been estimated to be 26–85% (Easton et
al., 1993; Ford et al., 1994; Easton et al.,
1995; Ford et al., 1995). In BRCA2 muta-
tion carriers, the risk of ovarian cancer is
estimated to be less than 10% (Ford and
Easton, 1995). The risk of ovarian cancer is
two-fold in BRCA1 mutation carriers who
also have one or two rare alleles of the
HRAS1 gene at 11p15.5 (variable number
of tandem repeats locus) (Phelan et al.,
1996). In HNPCC kindreds, the estimated
cumulative risk of ovarian cancer is 9%
(Aarnio et al., 1995). Overall, the current
risk estimates are based on studies of high
risk families collected for research purposes
and, thus, they may represent an overesti-
mate of the cancer risk associated with
BRCA1 and BRCA2 mutations.
7. Carcinogenesis
The genetic model of carcinogenesis has
been thoroughly investigated in colorectal
cancer (Fearon et al., 1990; Vogelstein and
Kinzler, 1993). Here, the gradually accu-
mulated genetic aberrations induce trans-
formation of normal colonic epithelium,
first to benign adenoma and eventually to
carcinoma. In ovarian carcinoma, our
knowledge of carcinogenesis is still limited.
Only a minor subset of tumors with benign
or low malignant potential are known to
progress to invasive carcinoma (Chuaqui et
al., 1997).
Carcinogenesis is a multi-step process.
It has been estimated that, depending on
the cancer type, 3–12 mutations are needed
for carcinogenesis to take place (Renan,
1993). During cancer development genetic
changes can accumulate in proto-oncogenes,
tumor suppressor genes and DNA repair
genes. Proto-oncogenes can be activated to
oncogenes by structural changes, point
mutations or amplifications, and lead to
changes in gene expression or proteins.
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Oncogenes are thought to have dominant
action at the cellular level, since alterations
in a single allele can cause malignant trans-
formation in the cell. Gene amplifications
can have clinical consequences, as shown in
patients with progressing solid tumors and
poor survival (Schwab and Amler, 1990).
Tumor suppressor genes, also called
“gatekeepers” (Kinzler and Vogelstein,
1997), suppress the development and pro-
gression of the malignant process. Accord-
ing to the two-hit theory, both alleles of a
gene have to be altered to inactivate the
gene (Knudson, 1971; Cavenee et al., 1983).
Usually, only one allele is mutated, somati-
cally or by an inherited trait, while the other
allele is deleted by another event. The
mechanism of allelic deletion may be loss
of the whole chromosome or part of it, or
mitotic recombination (Cavenee et al.,
1983). The DNA repair genes, also called
“caretakers” (Kinzler and Vogelstein, 1997),
act in the recognition and repair of DNA
damage. Germ-line mutations in the mis-
match repair genes are linked to the
HNPCC syndrome (Leach et al., 1993;
Nicolaides et al., 1994; Papadopoulos et al.,
1994; Edelmann et al., 1997; Miyaki et al.,
1997).
  
8. Methods for genome-wide
 screeningof DNA changes
8.1. Chromosome analysis
In human malignancies, chromosomal im-
balance in dividing cells has been widely
studied using conventional chromosome
analysis. Chromosomal examination of tu-
mor requires culturing of tumor cells, which
are then arrested in the metaphase or
prometaphase and stained for analysis. The
most common staining technique is the
Giemsa method (G-banding). Cytogenetic
analysis has proved to be valuable in study-
ing hematological malignancies. Much
fewer cytogenetic data are available on solid
tumors, especially carcinomas. This is due
in part to technical difficulties in studying
neoplastic epithelial cells, and to problems
in obtaining good quality metaphase
spreads for precise identification of chro-
mosomal changes. Tumor karyotypes are
often very complex, containing many
numerical and structural abnormalities that
make interpretation obscure. In addition,
those cells that can be cultured may not
necessarily represent the major tumor cell
clone. Some chromosomal changes, such as
small deletions and gene amplifications may
remain undetected. Moreover, identification
of the genomic origin of the double minute
chromosomes and homogeneously staining
regions, the cytogenetic manifestations of
gene amplification, cannot be carried out
by banding analysis. (Heim and Mitelman,
1995).
8.2. Fluorescence in situ hybridization
 (FISH)
Fuorescence in situ hybridization (FISH) can
be used to complement conventional chro-
mosome banding analysis. It allows higher
resolution of the chromosomal changes. In
addition, FISH can be used for studying
structural changes, such as translocations,
which may be difficult to find by conven-
tional cytogenetic analysis. Several appli-
cations of the FISH technique have been
developed. In chromosome painting, the
DNA probe is composed of a collection of
different DNA fragments from an indi-
vidual chromosome and, thus, the whole
chromosome will be stained. Chromosome
painting is useful for defining marker chro-
mosomes and recognizing chromosome seg-
ments. Furthermore, instead of using one
or two colors for detection of one or two
targets, several targets can be detected by
combining different fluorescent dyes (Ried
et al., 1992). New modifications of this
technique are multicolor FISH (Speicher et
al., 1996) and spectral karyotyping (Schrock
13
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et al., 1996), in which different chromo-
somal regions can be stained in various col-
ors. These techniques are useful for charac-
terization of marker chromosomes and de-
tection of subtle chromosomal  aberrations.
8.3. Comparative genomic hybridization
(CGH)
Comparative genomic hybridization was
introduced in 1992 by Kallioniemi and his
co-workers. The method allows whole ge-
nome detection and mapping of DNA se-
quence copy number changes in a single
experimental setting. It is based on simul-
taneous hybridization of differentially
fluorescently labeled test and normal DNAs
to normal metaphase chromosomes (Figure
1). The differences in binding of the test
versus normal DNA sequences to normal
metaphase chromosomes reflect the DNA
copy number variation between the test and
the reference genomes. The fluorescence
intensity ratios are measured in a digital
image analysis system. An increased test to
reference fluorescence intensity ratio sug-
gests gains or amplifications of DNA copy
number sequences in the test sample,
whereas a decreased ratio indicates losses of
the same (Figure 1).
The CGH method facilitates the study
of tumor samples for changes in DNA se-
quence copy number, whereas balanced
translocations, inversions or ploidy changes
are not detectable. The technique allows
detection of the changes present in a sub-
stantial proportion of tumor cells, provided
that the tumor cells predominate. The sen-
sitivity of the method depends on the size
and the magnitude of the copy number ab-
erration (Kallioniemi et al., 1994). Dele-
tions of 10–20 Mb in size have been reli-
ably detected by CGH (Bentz et al., 1998).
On the other hand, if the sequence is highly
amplified (up to 5–10 fold), changes as
small as 1 Mb in size can be seen (Forozan
et al., 1997). Some genomic areas, such as
the pericentromeric and the heterochro-
matic regions cannot be evaluated reliably
because they contain highly repetitive se-
quences which are blocked by unlabeled
human Cot-1 DNA. In telomeric regions,
the ratio changes should be interpreted with
caution because the fluorescence intensities
gradually decrease towards the telomeres,
approaching the background and, thus,
unreliable results may be obtained (Kallio-
niemi et al., 1994).
Several improvements have been made
in this methodology. Direct fluorochrome-
conjugated nucleotides have replaced the
indirect labeling system, improving reso-
Figure 1. The principle of comparative genomic
hybridization. Differentially labeled tumor and
normal DNAs are hybridized with Human Cot-1
DNA in normal metaphase chromosomes. Three
digital images are captured; one DAPI counter-
stain image, one FITC image for tumor DNA and
one TRITC image for normal DNA. Differences
in the tumor to normal fluorescence ratio on the
chromosomes reflect DNA copy number changes
in the tumor sample. The ratio difference is shown
as a profile.
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lution and sensitivity (Kallioniemi et al.,
1994). The use of paraffin-embedded tu-
mor material has allowed retrospective
analysis of archival tumors (Speicher et al.,
1993; Isola et al., 1994). Degenerate oligo-
nucleotide-primed PCR has facilitated the
use of very small amounts of DNA for
analysis (Speicher et al., 1993; Kuukasjärvi
et al., 1997). Recently, CGH has been suc-
cessfully used to study DNA from one cell
only (Klein et al., 1999). Ratio artefacts,
which may occur in the GC- rich genomic
regions, can be minimized by using a
mixture of dCTP and dUTP nucleotides in
the labeling of probes (El Rifai et al., 1997).
Four-color CGH modification was
developed to identify inconsistently
hybridized chromosomal regions and to
standardize the hybridization dynamics,
using internal control DNA (Karhu et al.,
1999). The resolution of CGH has been too
low to detect small amplifications or to
distinguish high-level amplification from
a low-level gain of a larger segment (Tanner
et al., 2000). To overcome the limited
resolution of chromosomal CGH, array-
based CGH has provided a means to increase
the mapping resolution (Solinas-Toldo et
al., 1997; Pinkel et al., 1998; Pollack et
al., 1999). In array-based CGH, cosmids,
PAC and BAC clones and cDNAs can be
used as targets of 0.5–2 kb in size (Pinkel
et al., 1998; Pollack et al., 1999).
8.4. Southern blot hybridization
Southern blot hybridization using gene- or
sequence-specific probes is suitable for
studying gene amplifications, deletions and
rearrangements. In Southern blot hybrid-
ization, size-fractionated, denaturated tar-
get DNA is transferred by blotting from
agarose gel to a nylon or nitrocellulose
membrane. Subsequently, the immobilized,
single stranded target DNA is hybridized
using radioactively labeled probes. The
probe will bind to complementary DNA
sequences in the target DNA only. The in-
tensity of the hybridization signal is quan-
tified by autoradiography and densitomet-
ric scanning, or by phosphor imaging.
 8.5. Loss of heterozygosity (LOH)
Loss of heterozygosity (LOH) analysis is
used for identifying allelic losses. In the
analysis, the polymerase chain reaction
(PCR) is used to detect the highly poly-
morphic microsatellite markers in paired
normal and tumor tissues. The analysis is
based on comparison of marker alleles in
paired normal and tumor DNA samples. If
the normal DNA is heterozygous for a given
marker and the tumor sample is homozy-
gous, it is considered as a loss of heterozy-
gosity. This can pinpoint the region possi-
bly harboring a tumor suppressor gene.
8.6. A new genome screening method, using a
cDNA microarray technique
Like the chromosomal CGH technique,
developed to an array, molecular analyses
have been similarly carried out by using
different arrays to obtain large scale infor-
mation on gene expression or protein lo-
calization (Schena et al., 1995; DeRisi et
al., 1996; Schena et al., 1996; Kononen et
al., 1998). A new approach is the so-called
complementary DNA (cDNA) microarray
technique, which allows simultaneous ex-
pression analysis of hundreds or even thou-
sands of genes in the sample of interest
(Schena et al., 1995; DeRisi et al., 1996;
Schena et al., 1996). In the cDNA array,
cDNA sequences can be immobilized on a
glass slide or a nylon membrane, and hy-
bridized with a labeled probe produced
from RNA of a tissue, cell line, or organism
of interest, to create a gene expression fin-
gerprint (Figure 2). Amplification of RNA
has enabled study of even small cell popu-
lations microdissected from a tissue section
(Gonzalez et al., 1999; Luo et al., 1999).
This large scale expression survey has
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been applied to investigate gene expression
changes in different human cancers. Re-
cently, studies have been performed on sev-
eral cell lines, such as alveolar rhabdomyo-
sarcoma cell line (Khan et al., 1998), HTLV-
1-immortalized T cells (Harhaj et al., 1999),
a glioblastoma cell line (Rhee et al., 1999),
and an ovarian cancer cell line (Ismail et al.,
2000). Gene expression profiles of 16 pri-
mary ovarian carcinomas have been reported
(Wang et al., 1999; Ono et al., 2000).
9. Chromosomal imbalance in ovarian
carcinoma
Cytogenetic studies of ovarian carcinoma
have revealed highly complex karyotypes
with multiple numerical and structural al-
terations, and with double minute chromo-
somes and homogeneously staining regions.
Cytogenetically abnormal cases have been
detected in 50–80% of cases (Pejovic et al.,
1992; Jenkins et al., 1993; Taetle et al.,
1999a). The majority have displayed com-
plex karyotypes; only a few tumors exhibit
simple changes, e.g. numerical changes
only, or a single structural change, or both.
In simple cases, the most common change
is to trisomy of chromosome 12 (Pejovic et
al., 1992a; Jenkins et al., 1993). In some
benign, borderline and malignant tumors,
trisomy 12 is the only cytogenetic aberra-
tion present (Pejovic et al., 1990; Pejovic
et al., 1992a; Jenkins et al., 1993; Thomp-
son et al., 1994). Frequently detected aber-
rations have been detected at chromosomes
1, 3, 6, 7, 11, 12, 19 and X (Wake et al.,
1980; Tanaka et al., 1989; Roberts and Tat-
tersall, 1990; Pejovic et al., 1992a; Jenkins
et al., 1993; Thompson et al., 1994; Taetle
et al., 1999a). Aberrations of chromosome
band 19p13 are relatively the most com-
mon (Pejovic et al., 1992a; Jenkins et al.,
1993; Thompson et al., 1994). The find-
ings, however, have varied in different stud-
ies, probably reflecting limited numbers of
observations, complexity of changes, or
methodological difficulties. Double min-
utes and homogeneously staining regions
have been reported with variable frequen-
cies (Tanaka et al., 1989; Bello and Rey,
1990; McGill et al., 1993; Thompson et
al., 1994). The clinical significance of cy-
togenetic changes has been assessed in some
studies (Roberts and Tattersall, 1990;
Pejovic et al., 1992b; Taetle et al., 1999b).
In the largest panel of samples (n=244),
breakpoints at 1p1 and 3p1 were associated
with poor survival (Taetle et al., 1999b).
Figure 2. The principle of the cDNA array tech-
nique. RNAs from test and reference samples are
converted to cDNA. The cDNAs are labeled with
radioactive 33P . The probes are hybridized to iden-
tical nylon membranes (arrays) containing known
cancer-related genes. After hybridization, the
membranes are exposed to an imaging plate and
subsequently scanned for computer analysis. In the
analysis, the membranes are overlapped for com-
parison
Test RNA Reference RNA
Test cDNA Reference cDNA
33P
Hybridization
Analysis by computer
Filter 1 Filter 2
1 2
upregulation
downregulation
no change
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Cytogenetic abnormalities are more com-
mon in seropapillary tumors and in cases at
an advanced stage and with residual disease
after primary surgery (Pejovic et al., 1992b).
Complex changes correlate with poor his-
tological differentiation and/or unfavorable
outcome (Pejovic et al., 1992b; Taetle et
al., 1999b). Overall, complex karyotypes are
characteristic of tumors with moderate or
poor histological differentiation (Pejovic et
al., 1992a; Pejovic et al., 1992b; Thomp-
son et al., 1994).
10. Molecular genetic changes in
ovarian carcinoma
10.1. Sporadic ovarian carcinoma
As in other cancers, the roles of both
oncogenes and tumor suppressor genes have
been studied in ovarian carcinoma. The
ERBB2 gene is located at 17q12 and en-
codes a cell surface protein homologous to
epidermal growth factor receptor. Over-
expression or gene amplification of ERBB2
has been reported in 18–32% of ovarian
carcinomas (Slamon et al., 1989; Berchuck
et al., 1990; Zheng et al., 1991; Rubin et
al., 1993; Young et al., 1996). It has been
associated with poor prognosis (Slamon et
al., 1989; Berchuck et al., 1990), but later
studies have not confirmed the clinical im-
pact of overexpression of ERBB2 (Rubin et
al., 1993; Singleton et al., 1994).
The KRAS gene is a member of the ras
gene family and is located at 12p12.1. It
encodes p21/k-ras 2a transforming protein,
localized to the cytoplasmic side of the in-
ner plasma membrane, and appears to be
involved in cell surface receptor signal trans-
duction. In epithelial ovarian tumors, mu-
tations of the KRAS gene are more com-
mon in mucinous tumors than in other his-
tological subtypes (Enomoto et al., 1990;
Ichikawa et al., 1994). KRAS mutations
have also been detected in benign adenomas
and borderline tumors with mucinous his-
tology (Mok et al., 1993; Teneriello et al.,
1993; Ichikawa et al., 1994; Chenevix-
Trench et al., 1997).
Several other oncogenes have been shown
to be amplified and/or overexpressed in ova-
rian carcinoma, such as AIB1 (in 25%) (Tan-
ner et al., 2000), CMYC (25–38%) (Zhou
et al., 1988; Baker et al., 1990; Sasano et
al., 1990; Tashiro et al., 1992), INT2 (19%)
(Medl et al., 1995), AKT2 (12–13%)
(Bellacosa et al., 1995; Cheng et al., 1992)
and CMET (28%) (Di-Renzo et al., 1994).
Some tumor suppressor genes have been
found to be involved in ovarian carcinoma.
Mutations of the tumor suppressor gene
TP53 at 17p13.1 are probably among the
most common genetic alterations found in
human cancer. In ovarian carcinoma, the
mutant TP53 protein has been detected in
about half of the tumors (Marks et al., 1991;
Hartmann et al., 1994; Klemi et al., 1995).
Mutations and overexpression have been de-
tected in advanced stage cancer more fre-
quently than in early stage cancer. Over-
expression of TP53 is associated with se-
rous histology, unfavorable outcome and
poor histological differentiation (Kupry-
janczyk et al., 1994; Klemi et al., 1995).
In benign cystadenoma, no overexpression
has been found (Marks et al., 1991). Positive
immunostaining, without mutations, has
been detected in borderline tumors (Kupry-
janczyk et al., 1994; Kupryjanczyk et al.,
1995).
The roles of other tumor suppressor
genes, such as RB1 (13q14), CDKN2
(9p21), DOC2 (5p13), BRCA1 and BRCA2
have also been studied. The role of RB1
seems to be insignificant, but inactivation
of CDKN2 occurs in about 20% of ovarian
tumors, especially in endometrioid and
mucinous tumors (Sasano et al., 1990;
Milde-Langosch et al., 1998). The DOC2
gene has been suggested to be involved in
serous ovarian carcinoma (Mok et al., 1998).
Mutations in BRCA1 and BRCA2 genes are
rare in sporadic ovarian carcinoma (Futreal
et al., 1994; Merajver et al., 1995; Takahashi
et al., 1995; Foster et al., 1996; Lancaster
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et al., 1996; Takahashi et al., 1996).
10.2. Inherited ovarian carcinoma
Some somatic molecular genetic changes
have been studied in BRCA1 and BRCA2
mutation-associated inherited ovarian car-
cinomas. TP53 mutations have been found
in 80% of the cases (83% of BRCA1 tu-
mors; 73–78% of BRCA2 tumors) (Rhei et
al., 1998; Ramus et al., 1999). TP53 mu-
tations appear to be more common in
BRCA1- and BRCA2-associated ovarian
carcinoma than in sporadic tumors (Ramus
et al., 1999). Point mutations of KRAS at
codon 12, or amplification of ERBB2,
CMYC or AKT2, which are common in
sporadic ovarian carcinoma, have not been
found (Rhei et al., 1998; Tanner et al.,
2000).
11. DNA sequence copy number
changes in ovarian tumors
Iwabuchi and co-workers (1995) published
the first CGH study on ovarian carcinoma.
Before this study was launched, reports on
genome-wide screening of DNA sequence
gains and losses in ovarian carcinoma were
not available. So far, some 340 cases of ova-
rian carcinoma have been studied using
CGH (Iwabuchi et al., 1995; Arnold et al.,
1996; Sonoda et al., 1997; Wolff et al.,
1997; Kudoh et al., 1999; Pejovic et al.,
1999; Blegen et al., 2000; Suzuki et al.,
2000; Kiechle et al., 2001) (Table 1). Chro-
mosomal changes have been found in 85–
100% of cases, which is slightly more than
in standard cytogenetic studies (Table 1).
This is probably due to the improved tech-
nology achieved using CGH compared with
cytogenetic methods. The findings in CGH
studies are referred to later in the Discus-
sion.
In addition to ovarian carcinoma, CGH
analysis has been performed on benign ova-
rian tumors. Results have been published
on 37 ovarian adenomas and tumors with
low malignant potential (LMP) (Iwabuchi
et al., 1995; Arnold et al., 1996; Sonoda et
al., 1997; Wolf et al., 1999; Blegen et al.,
2000). Many of the tumors have shown
alterations consistent with those in carci-
noma, suggesting the possibility that at least
some of the adenomas and LMP tumors may
be precursors of carcinoma. It is possible that
there are genomic changes in other benign
tumors as well, but CGH analysis is easily
Johanna Tapper
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compromised by contamination with nor-
mal cells. Twenty-one of the 37 tumors were
microdissected to enrich the tumor cell pro-
portion (Wolf et al., 1999; Blegen et al.,
2000).
12 . LOH in ovarian carcinoma
Numerous LOH studies on ovarian carci-
noma have been carried out to pinpoint the
regions possibly harboring tumor suppres-
sor genes. Studies have been performed ei-
ther by 1) mapping a chromosome with sev-
eral markers to narrow down the critical
region, or 2) screening with only a few
markers per chromosome to survey several
chromosomes for losses. In ovarian carci-
noma, varying frequencies of allelic loss have
been observed in all chromosomes (Sato et
al., 1991; Cliby et al., 1993; Dodson et al.,
1993; Yang-Feng et al., 1993; Launonen et
al., 2000). LOH has been found at several
genomic loci. Frequently lost regions have
been chromosomal arms 3p, 6p, 6q, 11p,
13q, 14q, 17p, 17q, 22q and Xp (Sato et al.,
1991; Eccles et al., 1992; Yang-Feng et al.,
1992; Cliby et al., 1993; Dodson et al., 1993;
Foulkes et al., 1993a; Foulkes et al., 1993b;
Weitzel et al., 1994; Phillips et al., 1996;
Bandera et al., 1997; Fullwood et al., 1999;
Bryan et al., 2000; Launonen et al., 2000;
Lin et al., 2000). However, LOH at
chromosome 17 has consistently been the
most common finding.
Chromosomal arm 17p has been screened
for LOH using several markers, and there
is evidence for the presence of other tumor
suppressor genes, apart from TP53. Schultz
and co-workers have defined the minimum
region of allelic loss at 17p13.3 between
markers D17S5 and D17S28, the estimated
genetic distance being 3.5 cM. In North-
ern analysis, mRNA expression of candidate
genes OVCA1 and OVCA2, located within
the above-mentioned region, is decreased in
ovarian carcinoma (Schultz et al., 1996).
The pattern of LOH correlates with the
histopathological characteristics of the tu-
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mor. Thus, LOH is more common in se-
rous than in nonserous tumors, and it is
more common in poorly differentiated than
in highly differentiated tumors (Sato et al.,
1991; Cliby et al., 1993; Dodson et al.,
1993; Saretzki et al., 1997). Deletions at
chromosome arms 6q, 13q, 17p and q, and
19q have been found more frequently in
serous than in nonserous tumors (Sato et
al., 1991; Saito et al., 1992; Pieretti et al.,
1995). LOH at chromosome arm 3p has
been detected more frequently in dissemi-
nated ovarian carcinomas than in local car-
cinomas (Fullwood et al., 1999). Further-
more, LOH at genomic regions 3p, 11p,
11q, 16q and 17p have been related to an
adverse disease course in ovarian cancer pa-
tients (Launonen et al., 2000).
On the basis of LOH data, it is possible
that inactivation of several tumor suppres-
sor genes occurs during progression of ova-
rian carcinoma. Despite the fact that LOH
is common in many genomic regions in
ovarian carcinoma, the tumor suppressor
genes in most regions have remained elu-
sive.
In ovarian carcinoma, the concordance
between CGH and LOH findings ranges
from 56% to 100% (overall concordance
84%) depending on the locus (Iwabuchi
et al., 1995). Only 31% of LOH has been
associated with losses detected by CGH
(Iwabuchi et al., 1995). However, the most
frequently lost regions in CGH also ex-
hibit LOH (Table 2). The discrepancy in
certain loci partly reflects the differences
in resolution between the methods, and
on the other hand, the different mecha-
nisms of LOH. If the LOH is due to physi-
cal deletion, CGH can reveal it. If the de-
letion is small or discontinous, or if the
LOH is due to mitotic recombination,
then CGH cannot detect it. If the LOH is
due to loss of one allele and the other allele
is amplified, then CGH may even indicate
amplification.
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AIMS OF THE STUDY
- to characterize the chromosomal changes
in sporadic and inherited ovarian carcino-
mas, as well as in fallopian tube carcinoma
(I-III)
- to compare chromosomal changes in dif-
ferent histological subtypes of ovarian car-
cinoma (I)
- to compare chromosomal changes in se-
rous carcinoma of the ovary, fallopian tube
and endometrium (II)
- to compare chromosomal changes in spo-
radic and inherited ovarian carcinoma (III)
- to screen and compare the gene expres-
sion changes in serous ovarian carcinoma
of different stages and histological grades
(IV)
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MATERIALS AND METHODS
1. Patients and tissues (I-IV)
All the studies were approved by the Insti-
tutional Review Board of the Department
of Obstetrics and Gynecology, Helsinki
University Central Hospital. In study I,
comparative genomic hybridization analy-
sis was performed on 24 samples of ovarian
carcinoma, including 8 serous, 8 endo-
metrioid and 8 mucinous carcinomas of
various stages, the patients being diagnosed
and treated at the Department of Obstet-
rics and Gynecology, Helsinki University
Central Hospital.
The material of study II consisted of 20
primary fallopian tube carcinomas, 20 ova-
rian carcinomas and 24 endometrial carci-
nomas (Pere et al., 1998), the patients be-
ing treated at the Department of Obstet-
rics and Gynecology, Helsinki University
Central Hospital. All the tumors were of
serous histology.
Study III comprised 20 inherited and 20
sporadic ovarian cancers. The samples from
patients with inherited ovarian cancer were
obtained from different hospitals in Finland.
The patients were members of breast-ova-
rian cancer families previously analyzed for
BRCA1 and BRCA2 mutations (Vehmanen
et al., 1997a; Vehmanen et al., 1997b), or
unselected mutation-positive ovarian can-
cer cases treated at the Department of Ob-
stetrics and Gynecology, Helsinki Univer-
sity Central Hospital. Sixteen of these pa-
tients were BRCA1 mutation-positive and
four were BRCA2 mutation-positive. His-
tologically, 14 tumors of the BRCA1 group
were serous cystadenocarcinomas, one was
an endometrioid adenocarcinoma and one
was a borderline mucinous cystadenoma. In
the BRCA2 group, three tumors were se-
rous cystadenocarcinomas, one of them pos-
sibly originating from the fallopian tube,
and one was an endometrioid adenocarci-
noma. The “sporadic” group (tissues also used
in study II) consisted of 20 serous ovarian
cystadenocarcinomas of similar stage and
grade. All the patients with sporadic cancer
were treated at the Department of Obstetrics
and Gynecology, Helsinki University Central
Hospital.
The study IV material comprised 6 ova-
rian serous cystadenocarcinomas and 1 be-
nign ovarian serous cystadenoma.
2. Methods
2.1. Comparative genomic hybridization (I-
III)
Genomic DNA from frozen tissues and pe-
ripheral blood from healthy female donors
was extracted by using standard methods.
DNA from paraffin-embedded tissues was
extracted according to the method de-
scribed by Isola and co-workers (1994).
Target metaphase slides were prepared from
phytohemagglutin-stimulated blood lym-
phocytes from normal donors (46,XX or
46,XY).
Comparative genomic hybridization was
performed as described previously (Kallio-
niemi et al., 1992; Kallioniemi et al., 1994),
with slight modifications (Figure 1).
In study I, tumor DNA and normal
DNA were labeled, by nick translation,
with biotin-14dATP (Gibco BRL, Gaithers-
burg, MD) and digoxigenin-11dUTP
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(Boehringer Mannheim, Mannheim, Ger-
many), respectively. The amounts of
DNAase and DNA polymerase I were ad-
justed to obtain probe fragments ranging
from 600–2000 base pairs. Equal amounts
(400 ng) of labeled tumor and normal fe-
male DNA, as well as 10 µg of unlabeled
human Cot-1 DNA (Gibco BRL, Gaithers-
burg, MD), were hybridized to normal
metaphase spreads at 37°C for 2–3 days.
After hybridization, the preparations were
washed to remove unbound DNA; three
times in 50% formamide/2xSSC (pH 7.0),
twice in 2xSSC, and once in 0.1xSSC, at
45°C for 10 minutes each. Tumor DNA was
visualized with tetra-rhodamine isothio-
cyanate (TRITC) -conjugated avidin and
normal DNA was detected with fluorescein
isothiocyanate (FITC) anti-digoxigenin.
The slides were counterstained with 4,6-
diamidino-2-phenylindole (DAPI) and cov-
ered with antifade solution (VectashieldTM,
Vector Laboratories, Burlingame, CA) for
identification of the chromosomes.
In studies II and III, the protocol was
changed to the use of directly fluorochrome-
conjugated nucleotides, to improve resolu-
tion and sensitivity (El Rifai et al., 1997;
Kallioniemi et al., 1994). Briefly, 1 µg tu-
mor DNA was labeled with FITC-12dUTP
(Du Pont, Boston, MA) or with FITC-
12dUTP and FITC-12dCTP (Du Pont)
(1:1), and 1 µg normal DNA was labeled
with Texas Red-5dUTP (Du Pont) or with
Texas Red-5dUTP and Texas Red-5dCTP
(Du Pont) (1:1) in standard nick transla-
tion. Equal amounts of labeled test and ref-
erence DNA were hybridized to normal
metaphase spreads for 2–3 days. After hy-
bridization, washing was carried out as de-
scribed above, followed by washing in
2xSSC in PN buffer (mixture of 0.1 M
NaH
2
PO
4
 and 0.1 M Na
2
HPO
4
, pH 8.0,
and Nonidet P-40), and in distilled water,
at room temperature for 10 minutes each.
In study III, the amount of DNA in one
sample was insufficient for CGH. This
sample was subjected to degenerate oligo-
nucleotide primed-PCR (DOP-PCR), fol-
lowing the protocol described by Kuukas-
järvi and her co-workers (1997), with some
modifications. Briefly, 5 µl of DNA solu-
tion was used as a template for DOP-PCR
with a universal primer 5’-
CCGACTCGAGNNNNNNATGTGG-3’
(N=A, C, G or T). Thermosequenase
(Amersham, Cleveland, OH) in a buffer (10
mM Tris-HCl, pH 8.0, 1 mM 2-mercapto-
ethanol, 0.5% Tween-20, 0.5% Nonidet
P40) was applied at 1:10 dilution (3 units/
reaction) in a solution of 26 mM Tris-HCl,
pH 9.5, 6.5 mM MgCl
2
, 0.2 mM dNTPs,
1 µM universal primer, the total volume
being 10 µl. The sample was subjected to
six cycles of 94.°C for 1 minute 30 °C for 3
minutes and 65°C for 5 minutes, with final
extension at 72°C for 10 minutes followed
by high stringency cycles consisting of ini-
tial melting at 95°C for 3 minutes, then
30–35 cycles of 94°C for 1 minute, 56°C
for 1 minute and 72°C for 2 minutes, with
final extension at 72°C for 5 minutes
(Thermocycler PTC-200, MJ Research Inc.
Watertown, MA), in a volume of 50 µl. The
product was labeled with fluorescein 12-
dUTP (Fluorescein-High prime kit, Boeh-
ringer Mannheim, Detroit, MI), using the
standard priming method recommended by
the supplier.
2.2. Digital image analysis in CGH (I-III)
The hybridizations were evaluated using a
Leitz (study I) or Olympus (studies II, III)
fluorescence microscope and an ISIS digital
image analysis system (MetaSystems
GmbH, Altlussheim, Germany), integrat-
ing a monochrome charge-coupled device
camera and an automated CGH analysis
software package. Three-color images, red
(TRITC) for tumor DNA hybridization
(study I), green (FITC) for normal reference
DNA hybridization (study I) or for tumor
DNA (FITC) (studies II and III), red
(TRITC) for reference DNA (studies II and
III) and blue (DAPI) for DNA counterstain,
23
Detection of prostate cancer
were acquired from 5 to 10 metaphase
spreads per hybridization (Figure 1). The
fluorescent background was reduced by au-
tomatic background correction. The homo-
geneous background allowed chromosome
segmentation by thresholding of the DAPI
image. The chromosomes were identified
and karyotyped on the basis of their DAPI-
banding patterns. Red and green fluores-
cence intensities were measured and the red-
to-green ratio (study I) or green-to-red ra-
tio (study II) profiles along the medial axis
from the p- to the q-telomere were dis-
played. For normalization of ratio profiles,
the modal value of the red-to-green (study
I) or green-to-red (studies II and III) ratio
for the entire metaphase spread was set to
1.0. This was repeated to analyze the pro-
files of all the metaphases included in the
analysis. The individual ratio profiles were
combined using separate normalizations of
the p- and q-telomeres to yield the average
ratio profiles that were displayed simulta-
neously next to the ideograms, with sig-
nificance intervals of 0.85 and 1.17, respec-
tively. In studies II and III, all the findings
were confirmed using a confidence interval
of 99%.
The chromosomal regions with a red-to
green ratio (study I) or a green-to-red ratio
(studies II and III) exceeding 1.17 were con-
sidered to be over-represented (gains),
whereas the regions with a ratio below 0.85
were considered to be under-represented
(losses). These values were set on the basis of
the results of negative control experiments
where two differently labeled normal DNAs
were hybridized together. In the negative
controls, the ratios varied within these limits.
Tumor DNA with a known number of copy
alterations was used in positive control
experiments. In study II, reverse labeling
CGH was performed in selected cases, which
confirmed the alterations detected by the
standard technique. The cut-off level for
high-level amplification was 1.5. Telomeric
and heterochromatic areas were discarded
from the analysis.
2.3. cDNA array (IV)
Frozen tissue samples were disrupted and
homogenized using an Ultra Turrax (Ika
Werk, Janke & Kunkel, Germany). Total
RNA from the tissue samples was isolated
by using Qiagen RNeasy Maxi Kit (Qiagen
Inc., Santa Clarita, CA) following the manu-
facturer’s instructions. After isolation, to-
tal RNA was purified from DNA by using
DNaseI (Boehringer Mannheim, Mann-
heim, Germany) enzyme incubation, sub-
sequently treating with phenol-chloroform-
isoamylalcohol, precipitating, and resus-
pending in RNase-free H
2
O. The integrity
of the RNA was confirmed by electrophore-
sis on 1% agarose gel.
A sample of total RNA (approximately 4
µg) was incubated with CDS Primer (Clon-
tech) at 70°C for 2 min and at 48°C for 2
min and subsequently reverse transcribed
and labeled with 33P dATP. The reverse-
transcribed probe was purified using a
Chroma Spin-200 column (Clontech),
denaturated and neutralized. The radiola-
beled cDNA probe was hybridized to a
membrane containing known cancer-related
genes (AtlasTM Human Cancer cDNA Ex-
pression Array, Clontech, Inc., CA), over-
night at 68°C in a hybridization oven (Mini
hybridization oven, Hybaid Inc.) with con-
tinuous rolling. After hybridization, the
membrane was washed at 68°C in 2xSSC,
1% SDS for 2 hours, and in 0.1xSSC, 0.5%
SDS for 1 hour. After the washes, the mem-
brane was sealed in a plastic wrap to prevent
drying, and exposed to a phosphor imaging
plate (Fuji Film, Japan) for four to six days
and scanned in a Bio-Imaging Analyzer
(BAS-2500; Fuji, Nakanuma, Japan).
The membranes were reused 3 to 4 times.
After exposure, they were stripped to re-
move the cDNA probe by boiling in 0.5%
SDS solution for 10–15 minutes. The effi-
ciency of stripping was checked by expo-
sure to a phosphor imaging plate overnight.
A single membrane contained cDNA
fragments from 588 human genes. Each
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cDNA fragment contained 10 ng cDNA,
and was immobilized in duplicate to en-
sure the quality of hybridization. The genes
in the membrane were subdivided into six
groups according to their function: a) cell
cycle and growth regulators, and interme-
diate filament markers, b) apoptosis-related
genes, oncogenes and tumor suppressor
genes, c) DNA damage response genes, re-
pair and recombination genes, cell fate and
development genes, and receptors, d) cell
adhesion and motility genes, e) invasion
regulators and cell-cell interaction genes,
and f) growth factors and cytokines. The
list of genes is available at Clontech’s web
site (http://www.clontech.com).
2.4. cDNA array analysis (IV)
The hybridization signals were analyzed by
using Atlas ImageTM 1.0 software (Clon-
tech). The two images to be compared were
normalized for the calculations by select-
ing and utilizing 7 out of 9 housekeeping
genes included in the membrane. In addi-
tion, the membrane contained three nega-
tive control DNAs in triplicate. The nega-
tive control spots had to be free of radioac-
tive signals. The results were visually con-
firmed. Selective analyses were repeated to
validate reliability and reproducibility of
the method.
To create gene expression fingerprint
profiles for ovarian carcinoma, the expres-
sion levels of the 588 known genes immo-
bilized on the membrane were analyzed.
The following comparisons were made: 1)
ovarian adenocarcinoma versus benign ad-
enoma, 2) local, highly differentiated ad-
enocarcinoma versus benign adenoma, and
3) advanced and/or moderately or poorly
differentiated ovarian adenocarcinoma
versus local, highly differentiated ovarian
tumor. The expression databases obtained
from the comparisons were sorted  the in-
tensity ratio values, in descending order.
The genes which showed an adjusted in-
tensity ratio above 2 or less than 0.5 in four
or more samples were considered to be dif-
ferentially expressed.
2.5. RT-PCR (IV)
RT-PCR was used to confirm the cDNA
array results of two genes, COL3A1 and
RHOGDI2. For reverse transcription reac-
tions we used random hexamer primers and
SuperScriptTM II RNase H- Reverse Tran-
scriptase (Gibco BRL, MD, USA). Gene-
specific PCR primer sequence information
was acquired from Clontech. As a reference
we used glyceraldehyde 3-phosphate dehy-
drogenase (G3PDH). The 50 µl PCR reac-
tion mixtures contained 1.0 unit of Perkin
Elmer AmpliTaq GoldTM (Roche Molecu-
lar Systems, Inc., NJ, USA) in 1x buffer
(GeneAmp 10x PCR Buffer II, Roche), and
1.5 mM magnesium chloride (Roche). The
reaction contained dNTPs (each 0.25 mM)
(Finnzymes, Espoo, Finland) and 20 pmol
of each primer. The PCR reactions included
initial denaturation at 95°C for 10 min,
followed by 25 to 30 cycles of 1 min at
95°C, 1 min at 56°C,  and 1 min at 72°C,
with 10 min final extension at 72°C.
2.6. Statistical analysis (III)
The differences in the frequency of copy
number changes between BRCA1 and “spo-
radic” groups were tested by using Fisher’s
exact test with two-tailed p-values.
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RESULTS
1. Summary of CGH results (I-III)
Altogether, 61 ovarian carcinomas were
studied by CGH. Two tumor specimens
used in study I, one serous and one endo-
metrioid tumor, turned out to be BRCA1-
and BRCA2 mutation-positive, respec-
tively. One sporadic tumor which was used
in study I was also used in study III as a
sporadic reference case. Fifty-seven tumors
(93%) exhibited DNA copy number
changes. Gains were more common than
losses, the ratio being 2.3:1. The most com-
mon gains affected 8q22-qter (54%). Other
common regions of gain were, in descend-
ing order of frequency, 7q21-q34 (36%),
3q21-q26 (34%), 1q25-qter (30%), 2q32
(26%) and 6p22 (26%) (cut-off 25%). The
most common high-level amplifications
were detected at 8q22-q24.1 (18%), 3q26.1
(8%), 1q32 (8%), 6p21 (7%) and 12p12
(5%) (cut off 5%) (Table 3). The most com-
mon losses were found at 8p21-pter (26%),
18q12-qter (18%), 17p (16%), 13q22-q31
and 18p (15%) (cut-off 15%). Chromo-
somes 19 and 20 were excluded from the
study I because some false-positive values
occurred in the negative control
experiments.
2. Sporadic carcinoma (I, III)
Forty-one sporadic carcinomas were stud-
ied using CGH analysis (Figure 3). Gains
were more common than losses, their ratio
being 2:1. On average, six aberrations per
tumor were detected. The most frequent
gain was found at 8q24.1-qter (54%). Other
common gains occurred at 1q31-qter
(29%), 7q21-q31 (29%) and 3q22-q26
(27%) (cut-off 25%). The most common
losses were at 8p21-pter, 9p21-p23 and
17p12-pter (20%). Other frequent losses
affected chromosomal regions 13q22-q31
(17%), 18q22 (15%) and 5q14 (15%) (cut-
off 15%).
2.1. Serous carcinoma (I, III)
Combining the serous tumors from studies
I and III, a total number of 26 tumors were
studied. Gains predominated over losses at
a ratio of 2.2:1. The most common gains
were at 8q24.1-qter (65%), 7q32-33 (35%),
3q25-26.3 (35%), 1q32-qter (31%), 5p15
and 6p22-pter (27%). High-level copy
number increases are shown in Figure 3.
The most common losses affected 8p22-
pter, 13q22-q31, 17p and 17q11.2-q21 (all
23%), 9p21-p23 and 18q22 (both 19%)
and 4q, 5q , 6q25-qter and Xq (all 15%).
2.2. Mucinous carcinoma (I)
In mucinous carcinoma, the gain to loss ra-
tio was 1.2:1. The most common region of
gain was 17qcen-q21, found in 6 out of 8
tumors (75%). The most common loss was
found at 9p in 3 out of 8 tumors (38%).
2.3. Endometrioid carcinoma (I)
In endometrioid carcinoma, gains were
more frequent than losses, the ratio being
1.9:1. The most common gains affected 1q,
in 4 cases out of 7 (57%), and 10q23-qter,
in 3 cases out of 7 (43%). The most com-
mon losses occurred at 8p21-pter and 18p,
in 2 out of 7 tumors (29%). One of the endo-
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metrioid tumors  included in study I re-
vealed a BRCA2 mutation.
2.4. Comparison of genetic changes
among different histological subtypes (I, III)
Serous carcinoma exhibited more chromo-
somal changes than mucinous or endo-
metrioid carcinomas, the average being
7.7 changes compared with 4.4 and 4.8
changes in endometrioid and mucinous
tumors, respectively. Gains at 1q occurred
in serous and endometrioid tumors only
(Table 4). High-level copy number in-
creases at 1q were common, especially in
endometrioid tumors. Gains at 5p were
observed only in serous carcinoma. Gains
and losses at chromosome 6 were detected
only in serous carcinoma, except for one
mucinous carcinoma showing a gain at 6p.
Losses at 8p were not found in the muci-
nous tumors and losses at 9p were not
found in endometrioid carcinoma. Gains
at chromosome 10 were not detected in
mucinous tumors. Gains at 11q were pre-
dominantly found in serous tumors; only
one endometrioid carcinoma showed a gain
at 11q. Losses at 13q were common in se-
rous carcinoma, whereas only one endo-
metrioid carcinoma revealed a loss at 13q.
Mucinous carcinoma did not show any
losses at 13q. Losses at 17p were not found
in endometrioid carcinoma. Gains at 17q
were most frequent in mucinous tumors.
Figure 3. Summary of chromosomal gains and losses in 41 cases of sporadic ovarian carcinoma. Each
line represents a change in one sample. Losses are displayed on the left and gains on the right of the
chromosomes. High-level amplifications are shown bold. Serous tumors are marked with a continuous
line, endometrioid tumors with a broken line and mucinous tumors with a dotted line.
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3. Fallopian tube carcinoma (II)
Twenty fallopian tube carcinomas were ana-
lyzed by CGH. DNA sequence copy num-
ber changes were found in all cases. Gains
were more common than losses, the ratio
being 1.6 to 1. The most common gains
were detected at 8q22-qter (75%) and
3q25-qter (70%). The other frequent gains
occurred at 1q and 12p (40%), at 7q (35%),
and at 5p and 20q (30%). High-level copy
number increases were found at 8q22-qter
(20%), 3q25-q28 (15%) and 12p (5%), in
a total of six tumors. The most common
losses affected 18q (35%), 8p and 5q (30%).
3.1. Comparison of genetic changes in serous
ovarian, fallopian tube and endometrial
carcinoma (II)
In serous carcinomas of the ovary, fallopian
tube and endometrium the pattern of chro-
mosomal changes was similar (Table 5). The
most commonly gained genomic regions,
i.e. 1q, 3q, 7q, 8q and 12p, and the most
frequently lost regions, i.e. 4q, 6q, 8p, 13q
and 18q, were similar in each cancer type.
Loss at 17p occurred only in ovarian and
fallopian tube carcinomas.
4. Inherited ovarian carcinoma (III)
Twenty cases of inherited carcinoma were
screened for somatic genetic alterations by
using CGH. Sixteen specimens were from
patients with BRCA1 mutations and four
tumors were from patients with BRCA2
mutations.
In the BRCA1 group, 13 of the 16 tu-
mors exhibited DNA sequence copy num-
ber alterations (average 6 changes per tu-
mor; SD 4.9) (Figure 4). Gains were three
times as common as losses. Eight of the 16
tumors (50%) carried gains at 2q24-q32,
3q25-q26.3, 7q31 and 8q22-qter. Five tu-
mors (31%) showed gains at 6p21.1-pter
and 11q21. High-level copy number in-
creases are displayed in Figure 4. The most
common loss was at 8p22-pter, found in 6
tumors (38%).
In the BRCA2 group, all four specimens
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Figure 4. Summary of chromosomal gains and losses in 16 cases of BRCA1- and 4 cases of BRCA2-
associated ovarian carcinoma. BRCA1-associated samples are marked with a continuous line and BRCA2-
associated samples are marked with a broken line. Each line represents one sample. Losses are shown on
the left and gains on the right of the chromosome. High-level amplifications are displayed bold.
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showed DNA sequence copy number
changes (Figure 4). Again, gains were more
common than losses. The most common
gains were found at 6p21.1-pter and 8q22-
qter (three out of four cases, 75%). High-
level copy number increases are shown in
Figure 4. Losses were detected at 8p21-pter
and Xq (in 2 out of 4 tumors; 50%).
4.1. Comparison of inherited and sporadic
 ovarian carcinoma (III)
Comparison of inherited and sporadic ova-
rian carcinoma revealed a similar pattern
of chromosomal aberrations except for chro-
mosomal gains at 2q24-q32 in BRCA1
mutation-associated tumors (Table 6).
Gains at 2q24-q32 were more common in
the BRCA1 mutation-associated serous can-
cers than in sporadic cancers.
5. Gene expression changes (IV)
5.1. Ovarian carcinoma versus benign ad-
enoma (IV)
All six adenocarcinomas were compared with
benign adenoma. Altogether, 59 different-
ially expressed genes were detected in adeno-
carcinoma. Thirty-eight of the genes were
upregulated and 19 were downregulated.
Sixteen genes were upregulated and nine were
downregulated in all carcinoma samples. The
upregulated genes included Rho family
genes, oncogenes and tumor suppressor
genes, genes for cell-cell interaction, inva-
sion, cell fate and development, apoptosis
regulators, cell cycle and growth regulators,
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growth factors, receptors, and DNA damage
repair. The downregulated genes included
Wnt pathway genes, genes for DNA dam-
age response and repair, invasion, angiogen-
esis, cell cycle and apoptosis regulators, re-
ceptors, intracellular kinase network mem-
bers, and intermediate filament markers.
5.2. Local, highly differentiated carcinoma
versus benign adenoma (IV)
A total of 49 genes were differentially ex-
pressed in local, highly differentiated carci-
noma compared with benign adenoma.
Twenty-three genes were upregulated and 26
genes were downregulated. The upregulated
genes included those for regulators of
apoptosis, cell-cell interaction, cell adhesion,
motility and invasion, intracellular network
members, invasion regulators, intermediate
filament markers, and receptors. The down-
regulated genes included those for cell adhe-
sion, motility and invasion, invasion regula-
tors, Wnt pathway genes, growth factors,
intermediate filament markers, cell-cell in-
teraction, receptors and tyrosine kinases.
5.3. Advanced carcinoma versus local, highly
differentiated carcinoma (IV)
Fifty-eight genes were differentially ex-
pressed in advanced carcinoma. In ad-
vanced carcinoma, 26 genes were up-
regulated and 32 were downregulated.
Twenty-one genes were upregulated and
12 genes were downregulated in all ad-
vanced carcinomas. In this comparison the
upregulated genes included cell adhesion
genes, motility and invasion genes, recep-
tor genes, oncogenes and tumor suppres-
sor genes, genes for cell cycle and growth,
cell fate and development regulators and
rho family members, DNA damage re-
sponse and repair genes, and cell-cell in-
teraction genes. The downregulated genes
included those related to apoptosis, intra-
cellular kinase network members, cyto-
kines and growth factors, DNA damage
response and repair, angiogenesis and cell
cycle and growth regulators, intermedi-
ate filament markers, invasion markers,
receptors and cell fate and development
regulators.
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DISCUSSION
Not more than ten years ago, a standard
cytogenetic technique was used as a screen-
ing method for chromosomal aberrations in
cancer research. This technique is still very
useful in studying hematological malignan-
cies, but it has clear limitations in study-
ing solid tumors, such as ovarian cancer.
Chromosomal analysis requires cell culture,
easily proliferating cells and good quality
metaphase spreads. Cells from solid tumors
do not grow well in cultures and the ob-
tained metaphase spreads are often difficult
to interpret. DNA-based methods have lim-
ited power in screening purposes because
specific probes are needed for the analysis.
These difficulties and limitations have led
to the development of CGH. It was a first
step towards the so-called array methods.
CGH provides whole genome screening and
mapping of chromosmal gains and losses.
Knowledge of chromosomal aberrations in
solid tumors has expanded rapidly (Knuu-
tila et al., 1998; Knuutila et al., 1999). Even
though CGH has proved its power in can-
cer research, it has certain limitations. It
can provide only a rough copy number
karyotype and, for example, translocations
and small changes cannot be detected. Tu-
mors consist of different cell populations
and clones, and usually different parts of a
tumor are not separated for the analysis. The
aberrations detected in a tumor represent a
“pool” of changes. This holds true for ova-
rian carcinoma. However, this can be
avoided by tissue microdissection, in which
specific parts or cells of the tissue can be
recovered (Gonzalez et al., 1999; Luo et al.,
1999). A recent development is the cDNA
array technique, which enables large-scale
and more detailed approaches. Arrays can
contain thousands of cDNAs representing
genes and ESTs. There are, however, cer-
tain requirements in using cDNA arrays.
The quality and quantity of RNA have to
be high. This requires careful handling of
specimens. According to the manufactur-
ers of the filter arrays, there is a risk of 10%
false-positive gene expression signals. In
addition, for data managment, sophisticated
bioinformatic systems are needed.
1. Chromosomal gains and losses in
ovarian carcinoma
On the basis of CGH analysis, ovarian car-
cinoma turned out to be genetically ex-
tremely complex. Only four carcinoma
samples exhibited a normal CGH profile.
Histopathological evaluation of the tumor
samples confirmed that the samples con-
sisted of more than 50% tumor cells. It is
possible that the samples without any DNA
sequence copy number changes still con-
tained other aberrations, such as ploidy
changes or balanced structural alterations,
that cannot be visualized by the CGH
method employed.
Nearly every chromosome was found to
contain alterations. Clustering of the DNA
copy number changes to certain chromo-
somal subregions was common (Figures 3
and 4). Some genomic regions with gains
are known to contain oncogenes obviously
playing a role in ovarian carcinoma. In the
present study, many other regions with
gains or losses were identified. In most of
the deleted regions the genes of importance
remain to be identified. In addition, CGH
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revealed several highly amplified regions
(Figures 3 and 4). These regions can be in-
formative in the search for putative ampli-
fied oncogenes (Tanner et al., 1994).
In keeping with the results of other stud-
ies, the most prominent gains in ovarian
carcinoma were detected at chromosome
arms 1q, 3q, 7q and 8q (Table 2) (Iwabuchi
et al., 1995; Arnold et al., 1996; Sonoda et
al., 1997; Wolff et al., 1997; Blegen et al.,
2000; Suzuki et al., 2000; Kiechle et al.,
2001). Chromosomes 19 and 20 were ex-
cluded from study I because some false-posi-
tive values occurred in the negative control
experiments. Chromosome 20, however, has
shown consistant gains in other studies
(Iwabuchi et al., 1995; Arnold et al., 1996;
Sonoda et al., 1997; Wolff et al., 1997;
Blegen et al., 2000; Suzuki et al., 2000;
Kiechle et al., 2001). Gains at the telomeric
part of chromosome arm 1q are also com-
mon in other cancers, but the candidate
genes have not yet been identified (Knuu-
tila et al., 1998). In solid tumors, changes
at chromosome arms 3q and 8q have been
associated with tumor progression (Isola et
al., 1995; Arnold et al., 1996; Heselmeyer
et al., 1996). Gain and high-level copy
number increases at 3q have also been
detected in many other cancers (Knuutila
et al., 1998). There are obvious candidate
genes at the telomeric part of chromosome
arm 3q. Recently, the PIK3CA gene, located
at 3q26, has been found to be amplified in
ovarian cancer (Shayesteh et al., 1999). It
encodes a subunit of phosphatidylinositol
3-kinase (PI3-kinase). Amplification of
PIK3CA is associated with PI3-kinase ac-
tivity. Many cancer-related functions, such
as proliferation (Klippel et al., 1998), cell
adhesion (Khwaja et al., 1997), apoptosis
(Kennedy et al., 1997) and RAS signaling
(Downward, 1998) have been associated
with PI3-kinase-mediated signaling. An-
other possible candidate gene, at 3q26.3,
is the human telomerase RNA gene (hTR),
which encodes telomerase, an enzyme which
maintains telomere length in the chromo-
somes. Telomeres are important for stabi-
lizing the chromosomes during replication.
Normal somatic cells undergo telomeric
attrition in the absence of telomerase ac-
tivity. It has been suggested that telomere
shortening may act as a molecular clock
(Holt et al., 1996). Telomerase activity has
been linked to cellular immortality and tu-
mor progression. Overexpression of telo-
merase has been found in ovarian carcinoma
(Soder et al., 1997; Soder et al., 1998).
At chromosome arm 7q a common re-
gion of gain extended from band q21 to
q33. A potent candidate gene at 7q31 is
the CMET gene, which codes for a trans-
membrane tyrosine kinase receptor and is
the ligand for hepatocyte growth factor/
scatter factor. CMET is expressed in
epithelial tissues, including normal
epithelia of the female reproductive system
(Huntsman et al., 1999). Increased
expression of CMET has been found in
ovarian carcinoma (DiRenzo et al., 1994;
Huntsman et al., 1999). At chromosome arm
8q the smallest commonly gained region
included bands q24.1-qter. However, many
gains affected almost all of the long arm and
in some cases displayed a profile with two
peaks, one at 8q24.1-qter and another at
8q11-q21.1. High-level copy number
increases, extending from band q12 to qter
were common. A probable candidate gene
at 8q24.1 is the CMYC oncogene. It is
amplified in ovarian carcinoma (Zhou et al.,
1988; Baker et al., 1990; Sasano et al., 1990)
as well as in several other cancers (Bieche et
al., 1995; Sato et al., 1999). CMYC is a
transcription factor and it has a role in DNA
replication (Ryan and Birnie, 1996). It is also
known to induce apoptosis. However, the
large size of the amplicons at 8q indicates
that there may also be other important genes
located at 8q.
The most notable losses were at 8p
(26%), 13q (20%), 17p (16%) and 18q
(18%). These results are in accordance with
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those of previous and subsequent CGH
studies in which the frequencies of losses
have varied between 6 and 56% (Iwabuchi
et al., 1995; Arnold et al., 1996; Sonoda et
al., 1997; Wolff et al., 1997; Blegen et al.,
2000; Suzuki et al., 2000; Kiechle et al.,
2001). Variation of results between studies
may be due to differences in study popula-
tions and small numbers of cases studied.
Losses at 8p, the smallest common region
narrowed down to q21-qter, have been de-
tected in other tumors as well, especially
in prostate cancer (Cher et al., 1994;
Visakorpi et al., 1995). Loss at 8p has often
occurred simultaneously with a gain at 8q,
indicating isochromosome formation. Iso-
chromosomes are thought to result from
transverse division instead of longitudinal
division of the centromere, or from
translocation, or chromatid exchange
involving two homologous chromosomes
(de la Chapelle, 1982). Isochromosome
formation at 8q has been found in other
solid tumors as well (Castedo et al., 1991;
Cher et al., 1994). At 8p, LOH is common
in many solid tumors. In ovarian carcinoma,
LOH at 8p has been found in 26–40% of
cases (Cliby et al., 1993; Osborne and Leech,
1994). However, in these studies, fine
mapping of 8p has not been feasible because
of the limited number of polymorphic
markers used. Use of a dense map of
microsatellite markers has enabled the
detection of a high rate of LOH at 8p22-
p23 (Wright et al., 1998). Possible
candidate tumor suppressor genes at 8p22
are N33, MSR and FEZ1 (Cher et al., 1994;
Bova et al., 1996; MacGrogan et al., 1996;
Nihei et al., 1996; Ishii et al., 1999). The
data suggest that 8p could harbor several
tumor suppressor genes important in ova-
rian carcinoma.
The minimum common region of loss at
13q included bands q22-q31. The known
tumor suppressor genes at 13q are BRCA2
(q12) and RB1 (q14.3), but they reside out-
side the lost segment. In ovarian carcinoma,
LOH at 13q22-q31 has been reported in
23–30% of cases, but the number of cases
and markers studied has been limited
(Yang-Feng et al., 1993). In the present
study, all losses at 13q, except for one, oc-
curred in serous carcinoma. This is accor-
dance with the results of earlier LOH stud-
ies in which 13q losses were related to se-
rous histology (Sato et al., 1991). Recently,
13q21-q22 has been reported to show fre-
quent LOH in carcinoma of the prostate
(Hyytinen et al., 1999). It is likely that
there are still unknown tumor suppressor
genes at 13q that may play a role in ovarian
carcinoma.
Loss of the TP53 gene, located at
17p13.1, possibly explains most of the
17p losses. However, two interesting can-
didate genes, OVCA1 and OVCA2,
assigned to 17p13.3, may also contribute
to the losses at 17p. Decreased mRNA
expression of OVCA1 and OVCA2 have
been reported in ovarian carcinoma
(Schultz et al., 1996). Chromosomal
region 18q21-q23, commonly deleted in
ovarian and in fallopian tube carcinoma,
includes the well characterized tumor
suppressor genes DCC and Smad4. The
DCC gene encodes netrin receptor (Keino-
Masu et al., 1996). Netrin is a
chemoattractant needed for guidance of
developing axons in the nervous system
(Keino-Masu et al., 1996). Inactivation of
DCC has been found in several malignan-
cies, such as colorectal (Fearon et al.,
1990), breast (Devilee et al., 1991),
prostate (Gao et al., 1993), and pancreatic
cancers (Hohne et al., 1992). However, in
ovarian carcinoma, LOH has been found
at 18q21, but not at the DCC locus within
the same region. Smad4 is a member of
the Mad gene family. The Smad genes are
involved in signal transduction between
TGF beta receptors and the cell nucleus.
Smad4 inactivation occurs in about 50%
of pancreatic carcinomas but is uncommon
in other tumors, including ovarian cancer
(Hahn et al., 1996; Schutte et al., 1996;
Takakura et al., 1999).
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2. Comparison of chromosomal alter-
ations among the different histological
subtypes
The present results suggest that serous ova-
rian carcinoma displays more chromosomal
alterations than mucinous or endometrioid
carcinoma. This is in accordance with the
observation that, using conventional cyto-
genetic analysis, abnormal karyotypes are
more frequent in serous carcinoma (Pejovic
et al., 1992). In CGH analysis, different his-
tological subtypes of ovarian carcinoma ex-
hibit different genomic alterations. Differ-
ences were detected at 1q, 5p, 6, 8p, 9p,
10, 11q, 13q and 17. Of the known
oncogenes, INT2 and ERBB2 are located at
11q13 and 17q12, and the tumor supressor
genes DOC2, MTS1 and TP53 at 5p13,
9p21 and 17p13, respectively. Molecular
genetic analyses of TP53 (Klemi et al.,
1995), KRAS (Enomoto et al., 1990; Mok
et al., 1993; Ichikawa et al., 1994), BCL2
(Diebold et al., 1996) and DOC2 (Mok et al.,
1998) have indicated genotypic differences
between various histological subtypes of
ovarian carcinoma. In LOH analysis, changes
at chromosome arms 6q, 13q and 19q have
been linked to serous histology (Sato et al.,
1991). The present results suggest that the
different histological subtypes of ovarian
carcinoma may have distinct genetic
pathways during carcinogenesis and tumor
progression. However, in CGH studies the
numbers of endometrioid and mucinous
tumors have been too small to allow any firm
conclusions to be made (Iwabuchi et al., 1995;
Arnold et al., 1996; Sonoda et al., 1997; Wolff
et al., 1997; Blegen et al., 2000; Suzuki et
al., 2000;  Kiechle et al., 2001).
3. Chromosomal gains and losses in
 fallopian tube carcinoma and com-
parison with changes in serous ova-
rian and endometrial carcinoma
The genetic background of fallopian tube
carcinoma is poorly understood. Molecular
genetic analyses concerning TP53, ERBB2
(Lacy et al., 1995) and KRAS (Mizuuchi
et al., 1995) in this tumor type have been
carried out, but only a few cytogenetic
studies have been reported (Bardi et al.,
1994). In studies using CGH, fallopian
tube carcinomas have shown extensive
genomic alterations. As in ovarian
carcinoma, the most common gains were
at loci 3q and 8q and the most frequent
losses were at 8p and 18q. The present
results agree with those of Heselmeyer and
co-workers (1998), who studied 12
primary fallopian tube carcinomas and
found the most frequent alterations to be
gains at 1q, 2q, 3q and 8q, and losses at
8p and 18q. They also found common
losses at 16q and 22q. In the present study,
frequent losses in these regions were not
detected. The discrepancy between the two
studies may involve the sensitivity of chro-
mosome 16 as regards artefacts, which may
lead to false ratio values. The relatively
small number of tumor samples analyzed
in both studies could also explain the
variation in the results.
Fallopian tube carcinoma also shared
other changes compared with serous ova-
rian carcinoma. The main pattern of aber-
rations resembled that found in serous
uterine carcinoma (Pere et al., 1998).
However, the changes were different from
those seen in other histological subtypes
of ovarian and uterine carcinoma (Pere et
al., 1998). Clinically, serous carcinomas of
the ovary, fallopian tube and endometrium
exhibit invasive behavior, early dissemi-
nation and are associated with poor sur-
vival (Blaustein, 1982). Histopathologi-
cally they are similar. TP53 mutations are
frequent in all these tumors (Klemi et al.,
1995; Lacy et al., 1995; Sherman et al.,
1995; Caduff et al., 1998). To summarize,
these similarities suggest that serous car-
cinomas of the ovary, fallopian tube and
endometrium may have a common genetic
pathway during tumor development and
progression.
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4. Chromosomal gains and losses in
inherited ovarian carcinoma and
comparison with the changes in
sporadic ovarian carcinoma
In addition to genetic predisposition,
i.e.,germ-line mutation of the BRCA1 or
BRCA2 gene and loss of the corresponding
wild-type allele, somatic genetic changes are
required for the malignant phenotype to de-
velop. In this study, somatic genetic changes
were screened by CGH. Inherited ovarian
carcinoma exhibited complex somatic ge-
nomic changes, so that almost every chro-
mosome appeared to contain genomic ab-
normalities. Clustering of the changes to cer-
tain chromosomal regions was observed. The
genomic abnormalities resembled those
found in sporadic serous ovarian carcinoma,
both qualitatively and quantitatively. The
most prominent gains affected the same ge-
nomic subregions as in sporadic carcinoma,
except for the gain at chromosome arm 2q.
Gains at 2q, the smallest common region
being 2q24-q32, were more frequent in
BRCA1-associated carcinoma compared
with sporadic carcinoma. The significance
of the 2q gain is, however, obscure. An in-
teresting gene at 2q34-q35, which is distal
to the minimum common region, is BARD1
(BRCA1-associated ring domain 1). BARD1
shares homology with two conserved regions
in the BRCA1 protein  (Wu et al., 1996). It
interacts with BRCA1, and is essential for
BRCA1-regulated tumor suppression (Wu
et al., 1996). In the 2q24-q32 region there
are many possible candidate genes, but none
of them has been studied so far by targeted
molecular genetic analyses in ovarian carci-
noma.
The BRCA1- and BRCA2-associated ova-
rian carcinomas show mainly serous histol-
ogy (Boyd and Rubin, 1997). The similar-
ity of the genomic changes in inherited and
sporadic serous ovarian carcinomas suggests
that serous ovarian carcinoma, irrespective
of its etiology, may follow a common main
pathway during tumor progression.
5. Gene expression changes in serou
 ovarian carcinoma
The cDNA array analysis of serous ovarian
carcinoma uncovered many genes with an
altered expression level. Some of the changes
found in this study, e.g. upregulation of
PCNA (Barboule et al., 1998), CMET (Di-
Renzo et al., 1994) and AKT2 (Bellacosa et
al., 1995), have been reported earlier in ova-
rian carcinoma. Our results thus confirm
earlier ones and provide further evidence of
the reliability of the cDNA array method
employed. Previous large scale expression
analyses of ovarian carcinoma (Wang et al.
199; Ono et al., 2000) and ovarian carci-
noma cell lines (Ismail et al., 2000) have
also revealed differences in many genes.
However, these studies cannot be directly
compared. In two previous studies of ova-
rian carcinoma the reference sample has
been normal ovarian tissue. In the present
study, normal ovarian tissue was not
included in the analysis. In addition, the
precise cDNA contents of the arrays used
in other studies are not known.
In the present study, the most prominent
differences between benign adenoma and
carcinoma were upregulation of RHOGDI2,
CMET and DLG3, and downregulation of
HGFAC, DES and PDGFRA. The
RHOGDI2 gene was upregulated in all cases
of carcinoma, irrespective of tumor stage,
suggesting that this gene may be essential
as regards serous ovarian carcinogenesis. The
RHOGDI2 gene acts as a regulator in the
guanine nucleotide di/tri phosphate (GDP/
GTP) cycle, and in cell membrane associa-
tion/dissociation of Rho proteins (Olofsson,
1999). The RHOGDI1 and Rho 8 genes were
also upregulated. The Rho family of pro-
teins are components in cellular processes
which control organization of the actin cy-
toskeleton, activate kinase cascades, regu-
late gene expression, promote growth trans-
formation and induce apoptosis (Zohn et
al., 1998). However, the role of RHOGDI2
in human carcinogenesis is unknown. The
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RHOGDI2 gene has not been linked to ova-
rian carcinoma before.
Comparison of local, highly differenti-
ated adenocarcinoma and benign adenoma
also revealed that the most highly up-
regulated gene was that for the cell divi-
sion cycle 42 homolog (cdc42). This gene
was also upregulated in advanced carci-
noma, but at a lower level than in local car-
cinoma. It has been suggested that cdc42
can alter regulation of normal cell growth
and initiate tumorigenic signals (Lin et al.,
1999). It is of interest that cdc42 is a Rho-
related GTP-binding protein. It may rep-
resent another mechanism by which the
Rho-pathway can play a role in the devel-
opment and progression of serous ovarian
carcinoma. There are no previous reports of
upregulation of cdc42 in ovarian carcinoma.
The most frequently downregulated gene
in ovarian carcinoma was that for hepato-
cyte growth factor activator (HGFAC). It
was downregulated in all carcinoma
samples, but the downregulation was not
as prominent in local, highly differentiated
carcinoma as in advanced cancers. HGFAC
is a serine proteinase that activates an inac-
tive, single-chain form of hepatocyte
growth factor (HGF). HGFAC is the key
enzyme that regulates the activity of HGF
in injured tissues (Miyazawa et al., 1996).
In glioblastoma, simultaneous expression
of HGF, HGFAC and the HGF receptor
gene CMET has been detected (Moriyama
et al., 1995). The downregulation of
HGFAC in ovarian carcinoma has not been
reported before.
 In this study, the most obvious differ-
ences between advanced and local carcinoma
were upregulation of COL3A1, FGFRI and
CMET, and downregulation of HGFAC,
FZD3 and BFL1. The gene for collagen type
III alpha 1 (COL3A1) was upregulated in
all three advanced carcinomas. The protein
is a component of soft connective tissue. It
has been suggested that progressive ovarian
carcinoma may induce expression of type
III procollagen both in the tumor tissue and
in the peritoneal cavity (Zhu et al., 1993).
In addition, in poorly differentiated serous
ovarian carcinoma, the formation of type III
procollagen may occur in the neoplastic cells
(Kauppila et al., 1996). In serous ovarian
carcinoma, production of type III pro-
collagen has been found to be related to an
increased degree of malignancy (Kauppila
et al., 1996). In breast cancer, the increased
synthesis of type III procollagen has been
suggested to play a role in tumor invasion
(Kauppila et al., 1998). Thus, it is possible
that upregulation of type III collagen may
also be involved in the progression of serous
ovarian carcinoma.
The present study showed differences in
gene expression between benign and ma-
lignant serous ovarian tumors, and between
local and advanced serous adenocarcinomas.
The limited sample size does not allow firm
conclusions. It can be speculated, however,
that the differentially expressed genes found
in malignant tumors may be associated with
carcinogenesis, whereas those genes which
are differentially expressed in advanced but
not in local carcinoma may play a role in
tumor progression.
6. The clinical significance of chromo-
somal changes
The clinical significance of chromosomal
gains and losses is still unclear. Tumors with
poor histological differentiation (grade) have
exhibited more changes than highly or
moderately differentiated tumors (Iwabuchi
et al., 1995). A high number of aberrations,
the presence of the most common changes,
e.g. gains at chromosomal arms 3q and 8q,
and loss at 16q, have been associated with
poor outcome (Iwabuchi et al., 1995; Suzuki
et al., 2000). Some alterations, such as gains
at 3q24-qter, 7p, 8q24 and 20q13.2-qter,
and losses at 11p and 13q, have been found
to be common in advanced stage and/or
poorly differentiated tumors, suggesting
that these changes are associated with dis-
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ease progression (Iwabuchi et al., 1995;
Sonoda et al., 1997; Kiechle et al., 2001).
In contrast, Suzuki and co-workers (2000)
have reported that gains at 3q, 8q and 20q
are common in well differentiated tumors.
To the list of changes in well differentiated
tumors can be added gains at 12p and 18p
(Kiechle et al., 2001).
Kudoh and co-workers (1999) studied
cisplatin resistance in ovarian carcinoma and
concluded that gains at 1q21-q22 and
13q12-q14 may be indicators of drug resis-
tance. This finding is different from that
regarding cisplatin-resistant ovarian carci-
noma cell lines, in which the critical chro-
mosomes have been reported to be 2, 4, 6, 7,
8, 11, 13 and X (Wasenius et al., 1997).
Consistent correlations between genetic ab-
errations and clinical behavior have not been
demonstrated, probably due to the limited
number of tumors studied, the genetic com-
plexity of the tumors and the wide spectrum
of their biological properties.
The findings of the present study do
not have straight clinical correlations or
applications. However, the identification
of specific genetic changes in different his-
tological subtypes of ovarian carcinoma
may be an important step on the road to
development of more individual cancer
therapy. The similarity of the changes de-
tected in serous carcinomas of the female
reproductive organs, i.e. ovary, fallopian
tube and endometrium, may be of help in
understanding the clinically similar behav-
ior of these cancers. In general, the genetic
changes linked to ovarian carcinoma can
help us to find new prognostic markers.
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SUMMARY AND CONCLUSIONS
The aim of the present study was to inves-
tigate the molecular cytogenetic and mo-
lecular genetic changes in ovarian carci-
noma. Comparative genomic hybridization
(CGH) analyses were performed on both
sporadic and inherited ovarian carcinomas,
including different histological subtypes.
The study was further extended to serous
carcinomas of the fallopian tube and the
endometrium to clarify the genetic relation-
ship between serous carcinoma of the dif-
ferent reproductive organs. In addition, a
large scale survey of gene expression changes
was performed in serous ovarian carcinoma
of different stages and histological grades.
Comparative genomic hybridization re-
vealed complex chromosomal aberrations in
ovarian carcinoma. Almost all chromosomes
showed abnormalities. Chromosomal gains
predominated over losses. Clustering of the
gains to chromosomal arms 1q, 3q, 7q and
8q, and losses at arms 8p, 13q, 17p and 18q
were detected. The most frequent high-level
amplifications occurred at chromosomal
bands 1q32, 3q26.1, 6p21, 8q22-q24.1 and
12p12.
In the CGH analysis, the most common
histological subtypes (serous, mucinous and
endometrioid) of ovarian carcinoma dis-
played distinct changes. This suggests that
different histological subtypes may have
different pathways of tumor development
and progression. When comparing serous
carcinoma of the ovary, fallopian tube and
endometrium, the most common genomic
changes affected the same chromosomal re-
gions in all cancers. It is thus possible that
serous carcinoma of the ovary, fallopian tube
and uterus share genetic changes needed for
tumor evolution. Sporadic serous ovarian
carcinoma and BRCA1- and BRCA2-asso-
ciated ovarian carcinoma, which are also of
serous histology, displayed strikingly simi-
lar genomic changes, except for gains at
chromosome arm 2q. Gains at 2q24-q32
were more frequent in BRCA1-associated
carcinoma than in sporadic carcinoma. This
indicates that serous carcinoma of the ovary,
despite the etiological differences in spo-
radic and inherited tumors, may follow a
common pathway during tumor progres-
sion.
The cDNA array analysis uncovered dif-
ferences in gene expression between benign
and malignant serous ovarian tumors, and
between local and advanced serous carcino-
mas. It is possible that the differentially
expressed genes found in this study are as-
sociated with carcinogenesis and tumor pro-
gression.
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